Mass Tort SOL Windows: The Discovery Rule, Docket-Specific Deadlines, and Why Standard PI SOL Logic Doesn’t Apply
His asbestos exposure happened at a manufacturing plant in 1991. Thirty-one years before the diagnosis.
A lead vendor applying standard PI SOL logic would never generate this lead. The incident was 1991. Two-year SOL in Ohio. Window closed in 1993. Ancient history. Move on.
That vendor would be wrong. Specifically, they would be wrong to the tune of $500,000–$1,000,000+ in case value.
Under the discovery rule — which governs virtually every mass tort docket — the SOL window does not run from the exposure date. It runs from the date the claimant knew, or reasonably should have known, that their injury was caused by the defendant’s product.
This claimant received a mesothelioma diagnosis in 2022 and learned at that moment that his disease was caused by occupational asbestos exposure. His SOL clock starts in 2022. Not 1991.
His window is current. His case is viable. The law firm that understands this gets a $1,000,000 case. The law firm whose vendor applies PI SOL logic never sees this claimant.
This is the most expensive mistake in mass tort lead generation. It doesn’t show up as a cost. It shows up as a case your competitor signed that you never knew existed.
PI SOL and Mass Tort SOL Are Not the Same Clock
Most law firms and most lead vendors treat mass tort SOL the way they treat PI SOL. That is the root of the problem.
PI SOL is simple. Car accident March 15, 2024. Two-year SOL in most states. Window closes March 15, 2026. The clock starts on the incident date. Everyone knows when the incident happened. Countdown from a fixed point.
Mass tort cannot work this way. The exposure and the harm are separated by years or decades. The claimant did not know they were harmed at the time of exposure. They couldn’t have known. The causal connection wasn’t established, wasn’t public, or wasn’t personally known to them.
A firefighter who worked with AFFF firefighting foam throughout the 1990s did not know in 2001 that PFAS compounds were accumulating in his body and would eventually cause bladder cancer. He found out in 2021 when his oncologist mentioned the connection during his diagnosis. His SOL clock starts in 2021. Not when he first picked up the hose. Not when he retired from the department.
A woman who received Depo-Provera injections for birth control from 2013 to 2017 did not know in 2018 that the drug was linked to meningioma brain tumors. That scientific connection wasn’t publicly established until the March 2024 study. She was diagnosed with meningioma in 2022. Her discovery moment — when she learned the connection — arguably comes in 2024 when she saw news coverage of the study. Her SOL clock arguably starts then.
Apply standard PI SOL to either of these claimants — “did this happen within the last two years?” — and both get rejected as expired. One of them is a $500,000 AFFF case. One of them is a six-figure Depo-Provera case. Both viable. Both gone.
The discovery rule exists because courts recognized that applying an incident-date SOL to latent-harm cases would make every mass tort claim time-barred before the plaintiff ever knew they had one.
Three Variables. All Three Required.
Standard PI SOL verification asks one question: how long ago did the incident happen?
Mass tort SOL verification requires three separate determinations. A vendor who can only answer one of them is doing PI logic on a mass tort product.
Variable 1: When Did the Discovery Clock Start?
This is the core discovery rule question. Not when was the claimant exposed. Not when did they receive a diagnosis. When did they know — or when should a reasonable person with access to the same information have known — that their specific injury was caused by the specific product?
The answer varies by docket and by claimant. Two people with the same AFFF exposure history and the same bladder cancer diagnosis may have different discovery dates depending on when each of them learned about the PFAS-cancer connection. One firefighter attended an occupational health briefing in 2019 discussing PFAS risks — his awareness date may be 2019. Another had no exposure to that information until a plaintiff law firm advertisement in 2023 — his awareness date may be 2023.
A properly built mass tort qualification form doesn’t ask “when did this happen.” It establishes the timeline: when was the diagnosis, when did the claimant become aware of the potential product connection, and does the combination of those facts place them inside a viable window under the discovery rule.
Variable 2: What Is the Applicable State SOL Window?
The discovery rule determines when the clock starts. State law determines how long the clock runs once it starts.
Most states operate on a two-year SOL for personal injury claims. Some states are three years. Florida changed to two years after its 2023 tort reform. New York is three years for most personal injury. California is two years.
The state where the claimant resides, or where the exposure occurred, determines which state’s SOL applies. A claimant exposed to Roundup in California who now lives in Texas may have a different SOL calculation than a lifelong Texas resident with identical exposure history.
A vendor applying a single national SOL window across all states is getting this wrong for a meaningful percentage of claimants.
Variable 3: Are There Federal MDL Filing Deadlines?
This is the variable that gets skipped most often — and it’s the one that produces the most expensive errors.
Federal MDL courts have the authority to establish case management orders that set administrative deadlines — for plaintiff fact sheet submissions, initial disclosures, or in some cases filing deadlines — that operate separately from and sometimes earlier than state SOL windows.
A vendor who verified SOL using only state law missed this entirely. Firms that continued buying Camp Lejeune leads after August 2024 paid for leads that couldn’t become cases — because their vendor never checked for the federal deadline.
All three variables. Not one. Any mass tort SOL framework that only addresses one or two of these three is producing the wrong answer on some percentage of your leads.
The Discovery Rule Per Docket: Where the Clock Starts
Every active docket has its own discovery rule profile. The awareness event that starts the SOL clock differs by docket — and by when specific scientific evidence became publicly available.
| Docket | SOL Clock Starts | Key Awareness Event | Practical Window |
|---|---|---|---|
| AFFF | Diagnosis + PFAS awareness | Occupational briefings / 2021+ litigation | 2–3 yrs from diagnosis + awareness |
| Roundup | Diagnosis + glyphosate awareness | August 2018 Monsanto trial verdict | Pre-2018: scrutinized. Post-2018: from diagnosis |
| Depo-Provera | Diagnosis + Depo awareness | March 2024 scientific study | Fresh window from 2024 for most |
| Hair Relaxer | Diagnosis + relaxer awareness | October 2022 NIH study | Fresh window from 2022–2023 for most |
| NEC Formula | Parents’ awareness of formula causation | 2022–2024 litigation publicity | Fresh window for most families |
| Mesothelioma | Diagnosis date | Diagnosis itself (latent disease) | Always current from diagnosis |
Federal MDL administrative deadlines operate separately from state SOL windows and may close filing paths earlier. Always verify both independently.
AFFF / Firefighting Foam
The SOL clock starts when the claimant (a) received a qualifying PFAS-linked cancer diagnosis and (b) knew or should have known the diagnosis was connected to AFFF exposure. For firefighters who participated in occupational health programs tracking PFAS exposure, awareness may have come earlier than for civilian plaintiffs near military bases who had no occupational context. The practical qualifying window for most AFFF claimants: two to three years from diagnosis plus established awareness of the PFAS-AFFF connection. No single hard federal administrative deadline applies to individual cancer claims as of April 2026 — but that could change with a global settlement order.
Roundup
The SOL clock starts when the claimant received an NHL diagnosis and became aware of the Roundup-glyphosate-cancer link. The August 2018 Monsanto trial verdict — and the massive publicity surrounding it — is the key public awareness date. Courts have increasingly held that plaintiffs diagnosed before 2018 who didn’t file until 2022 or 2023 need to demonstrate why they shouldn’t have known about the glyphosate connection by 2018. Diagnoses from 2019 forward generally get a fresh window running from diagnosis date. Diagnoses from 2016 to 2018 require case-specific evaluation of when awareness existed.
Depo-Provera
The SOL clock for most claimants runs from the March 2024 scientific study that publicly established the meningioma connection. Women diagnosed with meningioma before March 2024 who were unaware of the Depo-Provera link have an argument that their awareness date is 2024, giving them a fresh two-to-three-year window. Women who were diagnosed post-March 2024 have a clear awareness date at or near diagnosis. The rapid MDL growth in 2025 and 2026 reflects this mass discovery event: millions of women suddenly had a fresh SOL window.
Hair Relaxer
The October 2022 NIH study linking chemical hair relaxer use to uterine cancer is the key public awareness date. Women diagnosed with qualifying cancers before October 2022 who used chemical relaxers have an argument that their awareness of the connection came with the 2022 study, opening a fresh window. As litigation advertising spread through 2023 and 2024, awareness became harder to disclaim for anyone diagnosed with uterine or ovarian cancer who had used relaxers. Diagnoses from 2022 forward with confirmed product use generally carry straightforward discovery rule analysis.
NEC Baby Formula
The discovery rule analysis here focuses on parents, not patients — the injured party is an infant who cannot file their own claim. The SOL clock typically runs from when the parents knew or should have known that their premature infant’s NEC was potentially caused by cow’s milk-based formula rather than by prematurity alone. Given the specialized medical knowledge required to understand NEC causation and the timing of litigation publicity, most qualifying families have relatively fresh discovery windows from 2022 to 2024 when the litigation became publicly known.
Mesothelioma
The discovery rule is well-established through decades of asbestos litigation case law. Mesothelioma is diagnosed — not suspected — when the cancer is present. Courts have consistently held that the SOL clock for mesothelioma starts at diagnosis because the disease is latent enough that earlier discovery wasn’t reasonably possible. Asbestos exposure from 1975, 1985, or 1995 does not start the SOL clock. The 2022 or 2024 mesothelioma diagnosis does. This is why mesothelioma remains an evergreen mass tort docket: every new diagnosis, regardless of when the exposure occurred, opens a fresh SOL window.
Two Ways Wrong SOL Logic Destroys Your Economics
Getting SOL wrong in mass tort is not a minor operational issue. It costs money in two directions at once.
A vendor applying “did this happen within the last two years?” to mass tort rejects every claimant whose exposure was more than two years ago. For mesothelioma — where exposure is always decades old — this logic rejects 100% of viable plaintiffs. For AFFF, Roundup, Hair Relaxer, and Depo-Provera, it rejects a substantial portion of the viable plaintiff pool because exposure predates the two-year window even though the discovery clock is recent.
Every rejected viable claimant is a missed case. At $100,000–$1,000,000+ in case value, the cost of incorrect SOL rejection is not measured per lead. It’s measured per case.
A vendor who applies discovery rule logic without accounting for federal MDL deadlines delivers claimants who appear SOL-viable under state law but are foreclosed by federal administrative cutoffs. Camp Lejeune post-August 2024 is the clearest example: every Camp Lejeune lead delivered after that date was worthless, regardless of state SOL analysis, because the federal filing path was closed.
Three Questions That Reveal Whether a Vendor Understands Mass Tort SOL
Don’t accept “SOL verified” as a complete answer. Three follow-up questions reveal whether the verification is real or a checkbox.
If they give you the same answer for every docket — “we verify based on when the claimant became aware of their injury” — without being able to specify the docket’s awareness event, they’re not doing docket-specific SOL analysis. They’re using a framework that sounds right but doesn’t reflect the actual litigation landscape.
Frequently Asked Questions
The firms getting burned on SOL in mass tort are not making legal errors. They’re making operational ones — buying from vendors who apply the same SOL logic to mass tort that works for MVA, without understanding that the clock works differently.
Getting both directions right — accepting viable claimants whose exposure was decades ago, and not delivering claimants closed out by federal deadlines — is what separates a real mass tort lead operation from a collection form with good marketing.
Your vendor either knows which direction each docket’s SOL clock runs. Or they don’t.
Ask the three questions. You’ll know in five minutes.
Discovery Rule. Docket-Specific. Every Lead.
SOL verified under the discovery rule for each docket. Federal MDL deadlines checked independently. No PI logic on mass tort products.